Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Clover Biopharmaceuticals Ltd. ( (HK:2197) ) just unveiled an announcement.
Clover Biopharmaceuticals Ltd. has announced that its subsidiary, Clover HK, received a notice from Gavi Alliance regarding the unilateral termination of their Advance Purchase Agreement and a claim for repayment of $224 million. Clover Biopharmaceuticals disputes the claim, asserting it is without merit and plans to defend itself vigorously. The company continues to focus on advancing its RSV vaccine candidate, SCB-1019, in a re-vaccination setting and as part of a respiratory combination vaccine.
More about Clover Biopharmaceuticals Ltd.
Clover Biopharmaceuticals Ltd. is a company in the biopharmaceutical industry, focusing on the development of vaccines, including COVID-19 and RSV vaccine candidates. The company is incorporated in the Cayman Islands and is listed on the Hong Kong Stock Exchange.
YTD Price Performance: 34.85%
Average Trading Volume: 1,618,911
Technical Sentiment Signal: Hold
Current Market Cap: HK$421.5M
Find detailed analytics on 2197 stock on TipRanks’ Stock Analysis page.